Literature DB >> 23359343

Inhibitory Effects of 5-Aza-2'-Deoxycytidine and Trichostatin A in Combination with p53-Expressing Adenovirus on Human Laryngocarcinoma Cells.

Ling-Yan Jiang1, Meng Lian, Hong Wang, Ju-Gao Fang, Qi Wang.   

Abstract

OBJECTIVE: To investigate the effects of 5-Aza-2'-deoxycytidine (5-Aza-Cdr) and trichostatin A (TSA) combined with p53-expressing adenovirus (Ad-p53) on Hep-2 cell line in vivo and in vitro, in order to explore its possibility in biological treatment of laryngocarcinoma.
METHODS: Effects of 5-Aza-Cdr and TSA in combination with Ad-p53 on Hep-2 cell line in vivo were determined by Cell Counting Kit-8 (CCK-8) assay. The effect of drug combination was calculated by Jin's formula. Effects on the cell line in vitro were investigated by establishing the nude mice model.
RESULTS: 5-Aza-Cdr and TSA showed inhibitory effects on the proliferation of Hep-2 cells in dose- and time-dependent manner. Ad-p53 can inhibit the growth of Hep-2 cells in vivo and in vitro. However, the combination of epigenetic reagents (5-Aza-Cdr/TSA) and Ad-p53 was less effective than individual use of Ad-p53. 5-Aza-Cdr and Ad-p53 inhibited the growth of transplanted tumors and reduced the volume of tumors, and the tumor volume of Ad-p53 group was significantly smaller than that of the control group (P<0.05).
CONCLUSION: Both epigenetic reagents (5-Aza-Cdr/TSA) and Ad-p53 can suppress cell proliferation on Hep-2 in vivo and in vitro and there may be some antagonistic mechanism between Ad-p53 and epigenetic reagents (5-Aza-Cdr/ TSA).

Entities:  

Keywords:  5-Aza-2'-deoxycytidine; Hep-2 cell line; p53-expressing adenovirus; trichostatin A

Year:  2012        PMID: 23359343      PMCID: PMC3555288          DOI: 10.1007/s11670-012-0232-6

Source DB:  PubMed          Journal:  Chin J Cancer Res        ISSN: 1000-9604            Impact factor:   5.087


  29 in total

Review 1.  Cancer epigenomics: beyond genomics.

Authors:  Juan Sandoval; Manel Esteller
Journal:  Curr Opin Genet Dev       Date:  2012-03-06       Impact factor: 5.578

2.  Epigenomics: novel aspect of genomic regulation.

Authors:  Hwan Sung Cho; Jong Ho Park; Young-Joon Kim
Journal:  J Biochem Mol Biol       Date:  2007-03-31

3.  Genistein reverses hypermethylation and induces active histone modifications in tumor suppressor gene B-Cell translocation gene 3 in prostate cancer.

Authors:  Shahana Majid; Altaf A Dar; Varahram Shahryari; Hiroshi Hirata; Ardalan Ahmad; Sharanjot Saini; Yuichiro Tanaka; Angela V Dahiya; Rajvir Dahiya
Journal:  Cancer       Date:  2010-01-01       Impact factor: 6.860

Review 4.  p53 tumor suppressor gene therapy for cancer.

Authors:  J A Roth; S G Swisher; R E Meyn
Journal:  Oncology (Williston Park)       Date:  1999-10       Impact factor: 2.990

5.  Multiple hepatic arterial injections of recombinant adenovirus p53 and 5-fluorouracil after transcatheter arterial chemoembolization for unresectable hepatocellular carcinoma: a pilot phase II trial.

Authors:  Geng Tian; Jiliang Liu; Jie Sui Ruming Zhou; Weihong Chen
Journal:  Anticancer Drugs       Date:  2009-06       Impact factor: 2.248

6.  Analysis of p53 gene polymorphisms and protein over-expression in patients with breast cancer.

Authors:  Mustafa Akkiprik; Ozgur Sonmez; Bahadir M Gulluoglu; Hale B Caglar; Handan Kaya; Pakize Demirkalem; Ufuk Abacioglu; Meric Sengoz; Aydin Sav; Ayse Ozer
Journal:  Pathol Oncol Res       Date:  2009-09       Impact factor: 3.201

7.  Adenovirus-mediated wild-type p53 gene transfer in combination with bronchial arterial infusion for treatment of advanced non-small-cell lung cancer, one year follow-up.

Authors:  Yong-song Guan; Yuan Liu; Qing Zou; Qing He; Zi La; Lin Yang; Ying Hu
Journal:  J Zhejiang Univ Sci B       Date:  2009-05       Impact factor: 3.066

8.  Gene silencing of MIR22 in acute lymphoblastic leukaemia involves histone modifications independent of promoter DNA methylation.

Authors:  Xiaoqing Li; Jun Liu; Rui Zhou; Shi Huang; Shiang Huang; Xian-Ming Chen
Journal:  Br J Haematol       Date:  2009-10-05       Impact factor: 6.998

Review 9.  Targeting p53 for enhanced radio- and chemo-sensitivity.

Authors:  Chao Lu; Wafik S El-Deiry
Journal:  Apoptosis       Date:  2009-04       Impact factor: 4.677

10.  Aberrant epigenetic silencing is triggered by a transient reduction in gene expression.

Authors:  Jon A Oyer; Adrian Chu; Sukhmani Brar; Mitchell S Turker
Journal:  PLoS One       Date:  2009-03-12       Impact factor: 3.240

View more
  5 in total

1.  Liriodenine induces the apoptosis of human laryngocarcinoma cells via the upregulation of p53 expression.

Authors:  Liang Li; Ying Xu; Binquan Wang
Journal:  Oncol Lett       Date:  2014-12-29       Impact factor: 2.967

2.  Long noncoding RNA NEAT1 inhibits the acetylation of PTEN through the miR-524-5p /HDAC1 axis to promote the proliferation and invasion of laryngeal cancer cells.

Authors:  Jiajia Zhang; Ping Wang; Yanli Cui
Journal:  Aging (Albany NY)       Date:  2021-11-27       Impact factor: 5.682

3.  Cytotoxicity and degradation product identification of thermally treated ceftiofur.

Authors:  Hong Zhang; Shiying Lu; Honglin Ren; Ke Zhao; Yansong Li; Yuting Guan; Hanxiao Li; Pan Hu; Zengshan Liu
Journal:  RSC Adv       Date:  2020-05-13       Impact factor: 3.361

4.  The synergistic effects of low dose fluorouracil and TRAIL on TRAIL-resistant human gastric adenocarcinoma AGS cells.

Authors:  Hong Zhu; Min Huang; Daoling Ren; Jianping He; Fen Zhao; Cheng Yi; Ying Huang
Journal:  Biomed Res Int       Date:  2013-11-13       Impact factor: 3.411

5.  CircPLEKHM3 acts as a tumor suppressor through regulation of the miR-9/BRCA1/DNAJB6/KLF4/AKT1 axis in ovarian cancer.

Authors:  Lei Zhang; Qing Zhou; Qiongzi Qiu; Ling Hou; Mengting Wu; Jia Li; Xufan Li; Bingjian Lu; Xiaodong Cheng; Pengyuan Liu; Weiguo Lu; Yan Lu
Journal:  Mol Cancer       Date:  2019-10-17       Impact factor: 27.401

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.